A series of ureido derivatives incorporating a highly derivatized quinolone scaffold were prepared by a succession of original steps. The lead molecules of these compounds are the quinolone antibacterials of the nalidixic acid/ciprofloxacin type and they target, similar to these clinically used agents, the DNA gyrase/topoisomerase IV of pathogenic bacteria. These new quinolones are claimed to act as efficient antibacterials against a large number of drug-resistant bacteria such as Staphylococcus spp., Enterococcus spp., Streptococcus spp., Acinetobacter baumannii, Bacteroides bivius, Burkholderia spp., Chlamydia spp., Chlamydophila pneumoniae.
Heterocyclic urea derivatives and methods of use thereof (WO2010142978) / C. T. Supuran;A. Scozzafava. - In: EXPERT OPINION ON THERAPEUTIC PATENTS. - ISSN 1354-3776. - STAMPA. - 22:(2012), pp. 193-197. [10.1517/13543776.2012.656594]
Heterocyclic urea derivatives and methods of use thereof (WO2010142978).
SUPURAN, CLAUDIU TRANDAFIR;SCOZZAFAVA, ANDREA
2012
Abstract
A series of ureido derivatives incorporating a highly derivatized quinolone scaffold were prepared by a succession of original steps. The lead molecules of these compounds are the quinolone antibacterials of the nalidixic acid/ciprofloxacin type and they target, similar to these clinically used agents, the DNA gyrase/topoisomerase IV of pathogenic bacteria. These new quinolones are claimed to act as efficient antibacterials against a large number of drug-resistant bacteria such as Staphylococcus spp., Enterococcus spp., Streptococcus spp., Acinetobacter baumannii, Bacteroides bivius, Burkholderia spp., Chlamydia spp., Chlamydophila pneumoniae.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.